Liposomal Transdermal Drug Delivery of Antidiabetic Agents: Formulation Strategies, Characterization, And Regulatory Perspectives: A Comprehensive Review

Abstract

Diabetes mellitus represents a chronic metabolic disorder affecting over 415 million people globally, necessitating innovative therapeutic approaches to improve patient compliance and glycemic control. Transdermal drug delivery systems (TDDS) have emerged as a promising alternative to conventional oral and parenteral routes, offering several advantages including avoidance of first-pass hepatic metabolism, sustained and controlled drug release, and improved bioavailability. Liposomal formulations, composed of phospholipids structurally similar to biological membranes, have demonstrated exceptional potential as carriers for antidiabetic drugs across the skin barrier. This comprehensive review examines the formulation strategies, characterization techniques, penetration mechanisms, and clinical applications of liposomal transdermal delivery systems for antidiabetic medications. The paper synthesizes recent advances in nanotechnology-driven formulations including conventional liposomes, transfersomes, ethosomes, and novel ultraflexible vesicular systems, while addressing critical challenges in regulatory compliance, stability, and clinical translation

Keywords

liposomes, transdermal drug delivery, antidiabetic drugs, Characterization, Formulation Methodologies

Introduction

1.1 Epidemiology and Clinical Significance of Diabetes Mellitus

Diabetes mellitus represents a chronic disease characterized by insufficient production of insulin by the pancreas or the inability of the body to utilize insulin effectively. The global prevalence of diabetes has reached approximately 415 million individuals, with projections indicating an increase to 642 million people by 2040. The disease manifests in two primary forms: Type 1 Diabetes Mellitus (T1DM), characterized by autoimmune destruction of pancreatic beta cells, and Type 2 Diabetes Mellitus (T2DM), which comprises approximately 90% of all diabetes cases and is associated with insulin resistance and progressive beta cell dysfunction. Current therapeutic strategies rely heavily on oral antidiabetic medications and insulin injections, both of which present significant limitations including poor bioavailability, frequent dosing requirements, and variable patient compliance.

1.2 Limitations of Conventional Antidiabetic Drug Delivery Systems

Conventional oral administration of antidiabetic drugs is constrained by several physicochemical and physiological barriers. First-pass hepatic metabolism significantly reduces the bioavailability of many antidiabetic agents, while gastrointestinal degradation compromises the efficacy of peptide-based therapeutics such as insulin. Oral formulations result in fluctuating plasma concentrations with pronounced peak-trough variations, creating risk of hypoglycemia and hyperglycemia. Additionally, frequent dosing regimens required by many antidiabetic medications substantially diminish patient compliance, leading to suboptimal glycemic control. Parenteral administration via subcutaneous injection, while circumventing gastrointestinal barriers, introduces patient inconvenience, pain, and psychological barriers to medication adherence.

1.3 Advantages of Transdermal Drug Delivery Systems for Diabetes Management

Transdermal drug delivery systems present a non-invasive alternative to oral and parenteral routes, offering multiple therapeutic advantages. These systems enable drugs to bypass hepatic first-pass metabolism, resulting in significantly improved systemic bioavailability. The skin's extensive vascularization, receiving approximately one-third of total cardiac output, facilitates drug absorption when delivery barriers are appropriately overcome. Transdermal systems provide sustained and controlled drug release at predetermined rates, enabling maintenance of therapeutic concentrations over prolonged periods and reducing dosing frequency. This sustained release profile is particularly advantageous for diabetes management, as it facilitates stable blood glucose control and minimizes hypoglycemic episodes compared to oral formulations. The non-invasive nature of transdermal administration enhances patient compliance, particularly among individuals with needle phobia or those experiencing difficulty with oral medication tolerance.

1.4 Liposomes as Advanced Drug Delivery Carriers

Liposomes are spherical vesicles composed of phospholipid bilayers with aqueous cores, possessing remarkable structural similarity to biological cell membranes. This inherent biocompatibility renders liposomes significantly safer and less toxic compared to synthetic polymeric carriers. The phospholipid composition of liposomes, featuring naturally derived or synthetic lipids, enables encapsulation of both hydrophilic and hydrophobic drug molecules within their aqueous cores and lipid bilayers respectively. Liposomal carriers demonstrate high drug encapsulation efficiency (frequently exceeding 90%), thereby maximizing the concentration of active pharmaceutical ingredients within the formulation. The nanoscale size of liposomes (typically 50-500 nm) facilitates intimate interaction with skin lipids and promotes penetration through the stratum corneum's intercellular lipid pathways. Additionally, liposomes protect encapsulated drugs from enzymatic degradation and oxidative stress, thereby extending the therapeutic half-life and improving stability.

2. STRUCTURE AND CLASSIFICATION OF LIPOSOMAL FORMULATIONS

2.1 Conventional Liposomes

Conventional liposomes represent the most extensively studied and clinically established lipid-based nanoparticle systems. These spherical vesicles consist of one or more concentric phospholipid bilayers surrounding an aqueous core. The basic liposomal formulation typically comprises phosphatidylcholine (PC) or phosphatidylethanolamine (PE) combined with cholesterol (CHOL) at specific molar ratios to optimize membrane fluidity and stability. Conventional liposomes are classified based on lamellarity into three categories: unilamellar vesicles (ULVs) with a single lipid bilayer, oligolamellar vesicles (OLVs) containing 2-10 bilayers, and multilamellar vesicles (MLVs) with numerous concentric bilayers. The lipid composition critically influences the biophysical properties including membrane fluidity, drug encapsulation efficiency, in vitro release kinetics, and in vivo pharmacokinetic behavior. For transdermal delivery of antidiabetic drugs, conventional liposomes serve as excellent reservoirs for sustained drug release, though their limited ability to penetrate intact stratum corneum has led to the development of enhanced formulations.

2.2 Transfersomes (Elastic or Ultradeformable Liposomes)

Transfersomes represent an advanced class of liposomal carriers designed to overcome the stratum corneum barrier through enhanced deformability and flexibility. These ultraflexible vesicles are formulated by incorporating edge activators (EA) such as Tween 80, sodium deoxycholate, or other amphiphilic molecules into the liposomal bilayer. The edge activators disrupt the packing density of lipid molecules, creating mechanical stress within the vesicle that facilitates shape deformation and membrane destabilization. This enhanced flexibility enables transfersomes to deform and squeeze through the narrow pores of the stratum corneum (typically 20-40 nm), effectively bypassing the primary skin permeability barrier. Transfersomes demonstrate superior skin penetration compared to conventional liposomes, with increased transdermal flux and deeper tissue accumulation. The responsiveness of transfersomes to the osmotic gradient present across dermal tissue further promotes passive transdermal permeation without requiring external energy input.

2.3 Ethosomes

Ethosomes represent a novel class of vesicular carriers specifically engineered to enhance transdermal drug penetration by incorporating high concentrations of ethanol (30-50% v/v) into their structure. These alcohol-containing liposomes combine the benefits of classical liposomes with the penetration-enhancing properties of ethanol, creating a hybrid delivery system. The ethanol component disrupts the lipid organization of the stratum corneum, reducing the barrier resistance and facilitating deeper drug penetration into viable epidermis and dermis. Ethanol simultaneously increases the fluidity of the liposomal bilayer, enhancing drug loading capacity and promoting fusion with skin lipids. Comparative studies have demonstrated that ethosomes exhibit superior skin penetration compared to conventional liposomes and hydroalcoholic dispersions, with steady-state permeation rates substantially higher than aqueous formulations. For antidiabetic drugs such as glimepiride, ethosomal formulations have demonstrated remarkable efficacy with reduced adverse effects and prolonged transdermal delivery compared to oral administration.

2.4 Transethosomes

Transethosomes represent a novel hybrid vesicular system combining the advantages of transfersomes and classical ethosomes into a single optimized carrier. These formulations incorporate both edge activators and ethanol within the liposomal structure, synergistically enhancing transdermal penetration and drug delivery efficiency. Transethosomes demonstrate superior flexibility and permeability compared to their parent formulations, enabling delivery of both hydrophilic and lipophilic molecules across the skin barrier. The combined mechanisms of action—mechanical deformability from edge activators and chemical penetration enhancement from ethanol—create a particularly potent delivery system for antidiabetic medications.

2.5 Nanostructured Lipid Carriers (NLC)

Nanostructured lipid carriers represent an advanced development incorporating both solid and liquid lipids within an imperfect lipid matrix. This hybrid lipid composition provides improved drug-loading capacity, better control over release kinetics, and enhanced stability compared to conventional liposomes. The solid lipid component provides structural rigidity and crystalline organization, while the liquid lipid introduces specific defects and discontinuities in the matrix that accommodate higher drug loading. For pioglitazone, a commonly prescribed antidiabetic agent, NLC formulations have demonstrated sustained release profiles with improved bioavailability and reduced dosing frequency.

3. FORMULATION METHODOLOGIES FOR LIPOSOMAL ANTIDIABETIC DRUG DELIVERY SYSTEMS

 

 

3.1 Thin-Film Hydration Method (Bangham Method)

The thin-film hydration technique represents the oldest, most common, and simplest method for liposome preparation, particularly suitable for small-scale formulations. This methodology involves three fundamental steps: (1) dissolution of lipids (phospholipids, cholesterol, and other components) in organic solvents such as chloroform, ethanol, or chloroform-methanol mixtures; (2) evaporation of the organic solvent using a rotary evaporator under reduced pressure to form a thin, homogeneous lipid film on the inner wall of a round-bottom flask; and (3) hydration of the lipid film with aqueous solutions containing the drug to be encapsulated. The hydration step may occur at room temperature or elevated temperatures above the lipid phase transition temperature to promote liposome formation. Upon hydration, the lipid molecules self-assemble into multilamellar vesicles (MLVs) through a spontaneous process driven by the amphipathic nature of phospholipids. The resulting liposomes are heterogeneous in size, typically ranging from 400 nm to several micrometers, necessitating subsequent sizing techniques to obtain desired particle size distributions. Advantages of the thin-film hydration method include simplicity, scalability, and suitability for encapsulating hydrophobic drugs with minimal organic solvent contamination. Disadvantages include limited control over particle size, relatively lower encapsulation efficiency for hydrophilic drugs, and time-consuming organic solvent removal processes.

3.2 Ethanol Injection Method

The ethanol injection method represents a rapid and reproducible technique for liposome preparation offering superior simplicity and scalability compared to traditional thin-film hydration. In this methodology, a solution of phospholipids dissolved in ethanol is rapidly injected into a stirred aqueous solution (typically using a syringe or automated system). The rapid dilution of ethanol below a critical concentration triggers spontaneous precipitation and self-assembly of phospholipid molecules into bilayer structures. As the ethanol concentration decreases in the aqueous phase, lipid solubility diminishes, causing the lipid molecules to aggregate and form planar bilayer fragments that subsequently fuse to generate closed unilamellar vesicles (ULVs). Complete ethanol evaporation is facilitated through dialysis or reduced-pressure rotary evaporation. The ethanol injection method produces small unilamellar liposomes (SUVs) and large unilamellar vesicles (LUVs) spontaneously, with typical particle sizes ranging from 80-170 nm. The method exhibits several significant advantages including rapid formulation (achievable within 15-30 minutes), high reproducibility, use of pharmaceutical-grade ethanol (non-harmful compared to chloroform), and straightforward scale-up potential. However, limitations include difficulty in completely removing residual ethanol (as ethanol forms azeotropes with water), production of heterogeneous liposome populations, and potential inactivation of temperature-sensitive biopharmaceuticals. Recent advances have developed automated high-throughput versions utilizing dedicated pipetting robots and dynamic light scattering plate readers, enabling rapid optimization and screening of formulation parameters.

3.3 Ether Injection (Vaporization) Method

The ether injection method employs similar principles to ethanol injection but utilizes diethyl ether or ether-methanol mixtures as solvents. In this technique, phospholipid solutions in ether are slowly injected into aqueous phases heated to 55-65°C to facilitate ether evaporation. The slower injection rate and elevated temperature promote more efficient solvent evaporation, resulting in preferential formation of large unilamellar vesicles (LUVs). A key advantage of the ether injection method compared to ethanol injection is the more efficient removal of organic solvent, as ether volatilizes readily at moderate temperatures. The heated aqueous phase encapsulates a large fraction of aqueous volume within liposomes, enabling encapsulation of 30-45% aqueous content (compared to optimal ethanol injection yielding up to 65% entrapment at specific conditions). This method proves particularly valuable for encapsulating hydrophilic macromolecules within large aqueous compartments.

3.4 Proliposome Method

The proliposome method represents a simple, one-step procedure particularly valuable for industrial-scale liposome production without requiring organic solvents such as chloroform. This technique involves initial preparation of a proliposome mixture containing lipids or phospholipids, ethanol, and specific water ratios. The proliposome mixture is heated to 60°C for 30 minutes to generate a molten mixture, followed by ethanol evaporation. Conversion of proliposomes to liposomes occurs through a simple dilution step with aqueous solutions, eliminating the need for complex or energy-expensive procedures such as sonication. This method has demonstrated remarkably high encapsulation efficiencies, with silibinin-loaded liposomes achieving >96% encapsulation efficiency with minimal batch-to-batch variability. The absence of pharmaceutically unacceptable solvents and energy-expensive procedures renders this method particularly suitable for formulating drug-sensitive antidiabetic compounds.

3.5 Post-Formulation Sizing and Optimization Techniques

Following initial liposome formation by any primary method, several sizing techniques are employed to achieve desired particle size distributions and homogeneity. Sonication involves application of ultrasonic energy to disrupt multilamellar vesicles into smaller unilamellar structures, resulting in particle size reduction to 50-100 nm. Extrusion through polycarbonate membranes of defined pore sizes (typically 0.05-10 μm) represents a controlled sizing approach performed above the lipid phase transition temperature, resulting in liposomes with narrow size distributions and predictable diameters. High-pressure homogenization forces liposome suspensions through narrow orifices under elevated pressure (typically 500-2000 bar), generating shear forces that reduce particle size to 50-200 nm with reproducible results. Microfluidic systems enable precise control over liposome formation parameters through rapid mixing of lipid and aqueous phases within microchannels, yielding uniform particle sizes and enhanced encapsulation efficiencies (up to 95% for certain cargo).

4. CHARACTERIZATION OF LIPOSOMAL ANTIDIABETIC FORMULATIONS

4.1 Particle Size and Size Distribution Analysis

Particle size represents a critical quality attribute directly influencing liposome pharmacokinetics, cellular uptake, and transdermal penetration. Dynamic light scattering (DLS), also known as photon correlation spectroscopy (PCS), represents the most commonly employed technique for determining liposome size and polydispersity index (PDI). This method measures the Brownian motion of particles in solution and correlates this motion with particle hydrodynamic diameter, providing both mean particle size and distribution information. Transmission electron microscopy (TEM) provides direct visualization of liposome morphology and ultrastructure, confirming spherical vesicle formation and revealing internal multilamellar architecture. Atomic force microscopy (AFM) enables measurement of individual liposome dimensions and surface characteristics with nanometer-scale resolution. For transdermal delivery applications, particle sizes below 100 nm significantly enhance stratum corneum penetration compared to larger vesicles exceeding 200 nm. Gel-based sizing through size-exclusion chromatography enables separation of liposomes based on hydrodynamic radius and isolation of monodisperse populations.

4.2 Encapsulation Efficiency and Drug Loading Assessment

Encapsulation efficiency (EE%) represents a fundamental parameter quantifying the percentage of drug successfully incorporated into liposomes relative to the initial drug amount. The determination of encapsulation efficiency requires separation of free (unencapsulated) drug from liposome-associated drug, accomplished through various techniques. Dialysis methods employ dialysis membranes to separate liposomal formulations (retained) from free drug (diffusing through pores). Gel-exclusion chromatography achieves separation based on size differences, with liposomes eluting early and free drug eluting late. Centrifugation-based approaches isolate liposomes through differential centrifugation, separating them from free drug in the supernatant. Ultrafiltration employs filter membranes of specific molecular weight cutoffs to separate drug-loaded liposomes from unencapsulated drug. After separation, drug content is quantified using high-performance liquid chromatography (HPLC) with UV detection, liquid chromatography-mass spectrometry (LC-MS), or spectrophotometric methods. Encapsulation efficiency is calculated using the formula: EE% = [(Initial drug - Free drug) / Initial drug] × 100. Studies demonstrate that encapsulation efficiency is substantially influenced by drug physicochemical properties, preparation methodology, and formulation composition. For griseofulvin-loaded liposomes, chloroform-dissolved drug exhibited 97.9 ± 0.3% EE compared to only 31.8 ± 0.9% for drug powder incorporation, highlighting the critical importance of drug solubility state. Drug loading percentage is calculated as [Drug encapsulated / (Lipids + Drug)] × 100 and represents the ratio of drug mass to total formulation mass.

4.3 Zeta Potential and Charge Characterization

Zeta potential measurements quantify the electrical surface charge of liposomal particles, providing critical information regarding electrostatic stability and aggregation resistance. This parameter is measured using dynamic light scattering-based systems (Zetasizer) under defined conditions, typically at 25°C and 90° scattering angle to minimize reflection and polydispersity artifacts. Negatively charged liposomes typically exhibit zeta potentials ranging from -20 to -60 mV, while positively charged carriers range from +20 to +60 mV. Higher absolute zeta potential values (>±20 mV) generally correlate with improved colloidal stability due to enhanced electrostatic repulsion between particles, reducing aggregation tendency. Silibinin-loaded liposomes demonstrated zeta potential of -26.2 ± 0.6 mV, indicating good electrostatic stability. Surface charge can be deliberately modified through incorporation of charged lipids (e.g., phosphatidic acid for negative charge, stearylamine for positive charge) or coating with mucoadhesive polymers such as chitosan. For transdermal delivery, optimal zeta potentials enable interaction with skin components while maintaining colloidal dispersion stability.

4.4 In Vitro Drug Release Studies

In vitro drug release testing represents a critical evaluation parameter predicting in vivo drug performance and providing quality control mechanisms for batch-to-batch consistency. The dialysis method, most commonly employed for liposomal formulations, involves placing drug-loaded liposomes in dialysis bags (appropriate molecular weight cutoff) suspended in release media maintained at 37°C with continuous gentle stirring. Samples are withdrawn at predetermined time intervals (typically 0.5, 1, 2, 4, 6, 8, 12, 24 hours) and analyzed by HPLC or UV spectrophotometry to determine cumulative drug release. The reverse dialysis method places liposomes in release media with dialysis membrane partitions, preventing direct contact while enabling drug diffusion. Fractional dialysis employs smaller dialysis units enabling higher sample throughput for formulation screening. In situ methods monitor drug release directly without removing samples, maintaining physiological conditions throughout the study. USP apparatus methods (I and IV) have been modified for liposomal products to accommodate vesicle size and stability requirements. Release media selection critically influences results, with phosphate-buffered saline (PBS) at pH 7.4 representing the most physiologically relevant medium for transdermal applications. Cumulative percentage drug release is calculated as: %Release = (Amount released / Total drug loaded) × 100. Kinetic modeling (zero-order, first-order, Higuchi, Korsmeyer-Peppas) determines the mechanism governing drug release (diffusion-controlled, erosion-controlled, or anomalous transport). Albendazole-loaded conventional liposomes released >80% drug within 30 minutes, while PEGylated liposomes released only 25% in the same period, demonstrating substantial impact of surface modification on release kinetics.

4.5 Stability Assessment and Storage Conditions

Liposomal formulation stability represents a critical parameter for regulatory acceptance and commercial viability. Physical stability encompasses assessment of particle size changes, zeta potential alterations, and morphological transformations during storage. Chemical stability monitoring includes evaluation of lipid peroxidation, drug degradation, formation of lysolipids (toxic lipid oxidation byproducts), and pH-dependent hydrolysis. Microbiological stability verification ensures absence of microbial contamination during extended storage. Temperature significantly influences liposomal stability, with refrigerated storage at 4°C generally maintaining superior stability compared to room temperature (25°C) or elevated temperatures (37°C). Storage temperature studies demonstrate that betacyanin-loaded liposomes retained 75.54% at 4°C, 67.57% at 25°C, and only 20.28% at 37°C after 21 days. Light exposure substantially degrades liposomal formulations through lipid peroxidation and oxidative degradation, with UV-A irradiation causing approximately 25.84% degradation, UV-B causing 32.88% degradation, and UV-C causing 35.68% degradation for SUV formulations after 4 hours of exposure. pH stability is maintained when formulations are stored at neutral pH (6.5-7.5), with acidic (pH 2-4) and basic (pH >8) conditions promoting lipid hydrolysis and drug leakage. Cholesterol incorporation and alpha-tocopherol addition substantially improve liposomal storage stability by reducing lipid peroxidation. Freeze-drying (lyophilization) extends shelf-life substantially, with reconstitution capability preserved when appropriate cryoprotectants (mannitol, trehalose, glucose) are incorporated. For regulatory compliance, FDA guidance requires physical, chemical, and microbiological stability studies conducted at multiple temperatures (4°C, 25°C, 40°C) over extended periods (typically 12-36 months), with in-use stability verification for reconstituted products.

5. MECHANISMS OF TRANSDERMAL PENETRATION

5.1 Stratum Corneum Barrier Structure

The stratum corneum represents the primary barrier to transdermal drug penetration. This specialized tissue exhibits distinctive brick-and-mortar architecture with corneocytes as bricks and intercellular lipid matrices as mortar. The lipid composition consists uniquely of ceramides, cholesterol, and free fatty acids, forming highly organized lamellar structures with extremely low hydration.

5.2 Liposomal Penetration Enhancement Mechanisms

Liposomes enhance transdermal drug penetration through multiple synergistic mechanisms. The nanoscale size enables accommodation within intercellular lipid pathways. Phospholipid composition exhibits structural similarity to biological membranes, enabling facile interaction with skin lipids. This lipid-lipid interaction promotes fusion with stratum corneum lipid matrix, releasing encapsulated drugs directly into skin.

6. FORMULATION DEVELOPMENT OF SPECIFIC ANTIDIABETIC DRUGS

6.1 Insulin Transdermal Delivery Systems

Insulin represents the gold-standard therapy for Type 1 diabetes, but its peptide structure renders it susceptible to gastrointestinal degradation. Transdermal insulin delivery has emerged as a promising alternative. Vesicle-entrapped insulin in transdermal patches applied to diabetic mice resulted in approximately 43% reduction in blood glucose levels. Ethosomal and transethosomal insulin formulations maintained plasma insulin concentrations for 7 times longer (15 hours) compared to subcutaneous injection. The ionic liquid-based microemulsion approach achieved 56% reduction in blood glucose levels with half-life >24 hours.

6.2 Gliclazide Liposomal Formulations

Gliclazide, a second-generation sulfonylurea, acts by stimulating insulin secretion. The poor aqueous solubility substantially limits patient compliance. Liposomal gliclazide formulations have demonstrated sustained-release properties with improved bioavailability. Transdermal gliclazide delivery via chitosan-coated deformable liposomes resulted in superior sustained reduction of blood glucose for 24 hours.

6.3 Pioglitazone Transdermal Liposomal Systems

Pioglitazone, a thiazolidinedione antidiabetic agent, exhibits poor aqueous solubility (BCS Class II). Pioglitazone exhibits favorable physicochemical properties including small molecular weight (356 Da), appropriate partition coefficient (log P 2.94), low melting point, and suitable pKa. Pioglitazone-loaded nanostructured lipid carriers demonstrated sustained release profiles with improved therapeutic efficacy. Quality-by-design optimized pioglitazone-loaded liposomes exhibited particle size of 134.87 nm with high encapsulation efficiency.

6.4 Glipizide Transdermal Delivery

Glipizide represents one of the most commonly prescribed antidiabetic agents. Chitosan-coated deformable liposomes for transdermal glipizide delivery demonstrated superior pharmacokinetic profiles with sustained blood glucose reduction over 24 hours. In vivo studies revealed that transdermal glipizide maintained therapeutic levels for substantially longer periods.

 6.5 Sitagliptin Liposomal Formulations

Sitagliptin, a DPP-4 inhibitor, exhibits low permeability (BCS Class III). Sitagliptin-loaded liposomes formulated by thin-film hydration demonstrated encapsulation efficiencies ranging from 85.93% to 95.22%, with particle size approximately 40 nm. Optimized sitagliptin liposomes exhibited significantly greater potency with therapeutic activity persisting for 4 hours.

6.6 Metformin Liposomal Systems

Metformin hydrochloride, the most prescribed first-line antidiabetic medication globally, exhibits poor bioavailability. Metformin-encapsulated liposomal vesicles demonstrated that the drug-loaded film method achieved maximum entrapment efficiency of approximately 65%. In vitro release studies demonstrated first-order release kinetics with sustained release profiles.

7. PENETRATION ENHANCERS AND SYNERGISTIC DELIVERY TECHNOLOGIES

7.1 Chemical Penetration Enhancers

Chemical penetration enhancers promote transdermal drug absorption through disruption of stratum corneum lipid organization. Propylene glycol demonstrated approximately 2-fold enhancement of pioglitazone transdermal flux. Transcutol enhances drug solubility through interaction with aqueous domains. Optimal concentrations vary based on enhancer type and target drug.

7.2 Iontophoresis for Enhanced Transdermal Delivery

Iontophoresis utilizes low-level electrical current (typically 0.3-0.5 mA/cm²). Electrical field creates electrokinetic effects and electroporation creating temporary aqueous pores. For insulin transdermal delivery, iontophoresis achieved 20% reduction in blood glucose levels.

7.3 Microneedle Technology

Microneedles represent minimally invasive devices with microscale protrusions (typically 100-1000 μm length). Solid microneedles create microscopic disruptions generating transient permeation pathways. Hollow microneedles enable direct injection into viable epidermis. Insulin-loaded dissolving microneedle patches demonstrated rapid insulin absorption.

7.4 Combination Approaches

Advanced penetration enhancement combines microneedle-induced barrier disruption with electrical stimulation. Microneedle pretreatment followed by iontophoresis significantly enhanced fluorescein isothiocyanate-dextran permeation.

7.5 Ultrasonic Enhancement

Low-frequency ultrasound (sonophoresis) at frequencies of 20 kHz demonstrates superior enhancement efficacy. Ultrasound-enhanced insulin transdermal delivery resulted in sufficient permeation to reduce blood glucose.

7.6 Photothermal Enhancement

Photothermal approaches utilize plasmonic gold nanorods in transdermal formulations. NIR irradiation causes photothermal effects disrupting skin barrier lipids. Combined gold nanorod treatment resulted in approximately 58% reduction in blood glucose levels.

8. PHARMACOKINETICS AND BIOAVAILABILITY

8.1 Bioavailability Enhancement Mechanisms

Liposomal formulations substantially improve bioavailability through multiple mechanisms. Encapsulation protects drugs from gastrointestinal enzymatic degradation and hepatic first-pass metabolism. Enhanced solubility and permeability facilitates greater absorption. Liposomes promote transcytosis across epithelial barriers. Sustained release maintains therapeutic concentrations. Targeting strategies can direct delivery to specific tissues.

8.2 Pharmacokinetic Parameters

In vivo pharmacokinetic studies evaluate absorption, distribution, metabolism, and elimination. Folic acid-functionalized insulin-loaded liposomes demonstrated approximately double hypoglycemic effect. Ethosomal insulin formulations maintained plasma insulin concentrations for 15 hours.

8.3 In Vitro-In Vivo Correlation

FDA regulatory guidance emphasizes establishment of IVIVC. Level A IVIVC demonstrates point-to-point correlation; Level B uses average relationships; Level C relates one dissolution time point to one bioavailability parameter. Pharmacokinetic-pharmacodynamic correlation coefficient of 0.9635 demonstrated excellent predictability.

8.4 Mass Balance Studies

FDA recommends mass balance studies determining the fate of drug substance. These studies quantify percentages of drug substance recovered as parent compound, metabolites, and unchanged drug. Mass balance must separately quantify liposome-associated drug versus free drug in plasma.

9. CLINICAL EFFICACY AND SAFETY

9.1 Glycemic Control and Blood Glucose Reduction

Clinical efficacy is evaluated by ability to reduce fasting blood glucose, postprandial glucose excursions, and glycated hemoglobin (HbA1c). Silibinin-loaded liposomes demonstrated superior glucose-lowering effects with 2-fold reduction. Transdermal glipizide achieved sustained reduction for 24 hours.

9.2 Pancreatic Function and Islet Preservation

Liposomal antidiabetic formulations demonstrate capacity to preserve pancreatic beta cell function. Silibinin-loaded liposomes increased pancreatic insulin production and improved islet morphology. Transdermal glipizide maintained superior beta cell mass.

9.3 Inflammation and Oxidative Stress Markers

Diabetes involves significant inflammation and oxidative stress. Silibinin-loaded liposomes substantially reduced serum C-reactive protein levels. Ethosomal formulations provided multimodal therapeutic benefits.

9.4 Renal and Hepatic Function Assessment

Antidiabetic medications may influence kidney and liver function. Silibinin-loaded liposomes reduced serum creatinine and alanine transaminase levels. Transdermal glipizide avoided excessive hepatic metabolism.

9.5 Safety Profile and Adverse Effects

Liposomal formulations demonstrate favorable safety profiles. Ethosomal glimepiride transdermal formulations showed reduced adverse effects. The avoidance of gastrointestinal side effects through transdermal delivery eliminates nausea and diarrhea.

10. REGULATORY CONSIDERATIONS AND GUIDELINES

10.1 FDA Guidance for Liposomal Drug Products

FDA issued comprehensive guidance addressing chemistry, manufacturing, and controls. Liposomal formulations are recognized as non-biological complex drugs requiring distinct regulatory approaches. Critical quality attributes include particle size, free versus encapsulated drug ratios, lamellarity, lipid impurities, lysolipid content.

10.2 In Vitro Release Testing

FDA emphasizes development and validation of appropriate in vitro release methods. Appropriate methods include dialysis, reverse dialysis, and modified USP apparatus approaches. Methods must demonstrate discriminatory power to differentiate batches.

10.3 Sterilization and Aseptic Filtration

Liposomal products cannot be terminally sterilized using conventional methods. Liposomal products require aseptic processing with at least two filtrations. Membrane pressure must not exceed maximum limits (typically 25-50 psi).

10.4 Stability Testing Requirements

FDA requires stability testing across long-term, intermediate, and accelerated conditions. For lyophilized liposomal products, additional stability data must demonstrate reconstitution conditions. Stability studies must track particle size changes, encapsulation efficiency, free drug levels, lipid content.

10.5 Bioequivalence Assessment

FDA recognizes that traditional bioequivalence approaches based solely on plasma drug concentrations prove inadequate. Complexity of liposomal formulations necessitates evaluation of liposome-specific characteristics. Product-specific FDA guidance provides recommendations for establishing bioequivalence.

11. LIMITATIONS AND CHALLENGES

11.1 Manufacturing Scale-Up and Reproducibility Issues

Manufacturing scale-up presents substantial challenges. Heterogeneity in liposome size and composition frequently increases with scale-up. Batch-to-batch variability remains a persistent concern. Microfluidic approaches enable improved control but face limitations in throughput.

11.2 Physical and Chemical Instability of Liposomes

Despite advances, liposomal formulations retain inherent instability challenges. Phospholipid hydrolysis generates toxic lysolipids. Lipid peroxidation generates harmful oxidation byproducts. Leakage reduces drug concentration and therapeutic efficacy. Aggregation increases particle size.

11.3 Limited Transdermal Flux and Penetration

Despite enhancements, transdermal penetration remains limited by stratum corneum barrier. Insulin molecular weight (approximately 5,808 Da) substantially exceeds typical <600 Da threshold. While liposomal delivery improves insulin transdermal flux, absolute permeation remains inadequate without additional technologies. Combination strategies introduce complexity.

11.4 Regulatory Pathway Complexity

Regulatory pathway involves substantially greater complexity. Liposomal formulations require distinct regulatory approaches. Absence of standardized test methods necessitates novel analytical method development. This increases development timelines and costs.

11.5 Cost of Goods and Commercial Viability

Liposomal formulations entail substantially higher manufacturing and quality control costs. Requirement for aseptic processing substantially increases costs. Liposomal products typically cannot achieve low cost structures of generic tablets. Limited patent protection complicates return-on-investment considerations.

11.6 Drug-Liposome Interaction and Stability Issues

Prolonged contact between encapsulated drugs and lipid membranes may result in unfavorable interactions. Lipophilic drugs may partition into lipid bilayer. Hydrophilic drugs may undergo leakage. Charged drugs may form ion pairs.

12. FUTURE PERSPECTIVES AND EMERGING TECHNOLOGIES

12.1 Stimulus-Responsive Liposomal Systems

Emerging research explores stimulus-responsive liposomes releasing drugs in response to biological triggers. pH-responsive liposomes enable delivery to specific tissue microenvironments. Temperature-sensitive liposomes release drugs in response to mild hyperthermia. Glucose-sensing liposomes enable insulin release proportional to blood glucose concentration.

12.2 Targeted Delivery to Pancreatic Islets

Advanced targeting strategies incorporating ligands on liposomal surfaces enable preferential accumulation. Folic acid-functionalized liposomes demonstrated improved cellular uptake. Pancreatic-specific antibodies or peptide ligands could enable selective delivery to beta cells. Targeted delivery minimizes systemic exposure while maximizing local concentrations.

12.3 Gene Delivery and Combination Immunotherapy

Emerging research explores liposomal delivery of genetic material including plasmid DNA, siRNA, and mRNA. Lipid nanoparticles achieved remarkable success in nucleic acid delivery. Combination approaches could address inflammatory components. Gene editing technologies combined with liposomal vehicles offer potential.

         12.4 Personalized Medicine and Patient-Specific Formulations

Future advances may enable patient-specific liposomal formulations. Pharmacogenomic approaches could identify optimal combinations. Personalized dosing algorithms incorporating continuous glucose monitoring could optimize therapy.

12.5 Combination Therapy with Complementary Agents

Future liposomal systems may incorporate synergistic combinations. Co-delivery of insulin with GLP-1 receptor agonists could provide superior control. Combination with antioxidants and anti-inflammatory compounds could provide comprehensive management.

CONCLUSION

Liposomal transdermal drug delivery systems represent a transformative approach to antidiabetic therapy. Structural versatility—from conventional vesicles to ultradeformable transfersomes and ethosomes—enables optimization for diverse antidiabetic agents. Comprehensive characterization methodologies provide robust quality assurance frameworks.

Recent clinical advances demonstrate remarkable efficacy in achieving sustained blood glucose reduction, preserving pancreatic beta cell function, reducing inflammatory markers, and maintaining favorable safety profiles. Combination penetration-enhancement strategies enable transdermal delivery of large molecular weight compounds. Substantial challenges remain in manufacturing scale-up, regulatory compliance, liposomal stability, and commercial viability. FDA's comprehensive guidance provides clear regulatory pathways, yet complexity remains substantial.

Future research emphasizes stimulus-responsive systems, targeted delivery, gene therapy, and personalized medicine approaches. Integration with emerging technologies offers potential to revolutionize diabetes management.

In conclusion, liposomal transdermal delivery systems of antidiabetic drugs represent a promising frontier with potential to substantially improve therapeutic outcomes, patient quality of life, and disease management globally. Continued research and development with regulatory collaboration will be essential to translate therapeutic potential into safe, effective, and commercially viable clinical products.

REFERENCES

1. Dinic S, Arambasic Jovanovic J, Uskokovic A, Jovanovic A, Grdovic N, Rajic J, et al. Liposome encapsulation enhances the antidiabetic efficacy of silibinin. Pharmaceutics. 2024;16(6):801.
2. Choudhury A, Kirti A, Lenka SS, Naser SS, Sinha A, Kumari S, et al. Strategic advances in liposomes technology: translational paradigm in transdermal delivery for skin dermatosis. J Nanobiotechnol. 2025;23(1):576.
3. Subash Chandran MP, Pandey VP. Formulation and evaluation of gliclazide loaded liposomes. Der Pharm Lett. 2016;8(11):60–8.
4. Ng LC, Gupta M. Transdermal drug delivery systems in diabetes management: a review. Asian J Pharm Sci. 2020;15(1):13–25.
5. Wang C, Wang Y, Lan X, Zhu L, Gu J, Liu W, et al. Multidimensional delivery strategies for liposomal transdermal drug delivery systems. ACS Mater Lett. 2025;7(5):1795–1806.
6. Nikam VD, Sonawane MP, Pawar KS, Rathod A, Tamboli A. An upgraded review: anti?diabetic medication administration by liposomal formulation. Asian J Res Pharm Sci. 2025;15(2):215.
7. Patil A, Shekade S. Transdermal delivery system for the treatment of diabetes mellitus: an overview. Int J Pharm Sci Nanotechnol. 2020.
8. Souto EB, Macedo AS, Dias?Ferreira J, Cano A, Zielinska A, Matos CM. Elastic and ultradeformable liposomes for transdermal delivery of active pharmaceutical ingredients (APIs). Int J Mol Sci. 2021;22(18):9743.
9. Rachel KF, Patil A. Development and characterization of anti?diabetic liposomal formulation. Int J Green Pharm. 2022;16(1):94–105.
10. Islam MR, Uddin S, Chowdhury MR, Wakabayashi R, Moniruzzaman M, Goto M. Insulin transdermal delivery system for diabetes treatment using a biocompatible ionic liquid-based microemulsion. ACS Appl Mater Interfaces. 2021;13(36):42461–42472.
11. Sudhakar K, Fuloria S, Subramaniyan V, Sathasivam KV, Azad AK, Swain SS, et al. Ultraflexible liposome nanocargo as a dermal and transdermal drug delivery system. Nanomaterials (Basel). 2021;11(10):2557.
12. Umar M, Sherazi TA, Talha M, Ramadan MF, Ahmed AE, Taha R, et al. Nanoliposome-based drug delivery systems for the treatment of diabetes mellitus: a review. RSC Adv. 2025;15(57):49119–49143.
13. Thirunavukkarasu A, Nithya R, Jeyanthi J. Transdermal drug delivery systems for the effective management of type 2 diabetes mellitus: a review. Diabetes Res Clin Pract. 2022;194:109996.
14. Akombaetwa N, Ilangala AB, Thom L, Memvanga PB, Witika BA, Buya AB. Current advances in lipid nanosystems intended for topical and transdermal drug delivery applications. Pharmaceutics. 2023;15(2):656.
15. Singh LS. Developing nanocarrier-based formulations of antidiabetic drugs derived from medicinal plants: a systemic review. Pharmacol Res Nat Prod. 2024;2:100004.
16. Kumbhar PS, Kolekar K, Nadaf S, Vishwas S, Kamble V, Bhagwat D, et al. Expanding the arsenal against diabetes mellitus via transdermal application of drug-loaded nanoparticles and microneedles: recent advances and future perspectives. J Drug Deliv Sci Technol. 2024;98:105930.
17. Ashtikar M, Nagarsekar K, Fahr A. Transdermal delivery from liposomal formulations: evolution of the technology over the last three decades. J Control Release. 2016;242:126–140.
18. Jaiswal A, Nigam C, Manjari P, Kaur I, Mamta, Singh MM, et al. Formulation and optimization of liposomal and niosomal systems for enhanced drug delivery in diabetes disease. Int J Environ Sci. 2025;11(22S):274–286.
19. Du G, Sun X. Ethanol injection method for liposome preparation. Methods Mol Biol. 2023;2622:65–70.
20. Oliveres R. LNP and liposomes characterization guidelines: size, PDI, morphology. Inside Therapeutics. 2025 Oct 2.
21. Oliveres R. Mastering thin film hydration method for liposome and LNP formulation. Inside Therapeutics. 2025 Oct 2.
22. Ong SGM, Long CM, Lee KS, Yuen KH. Influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Pharmaceutics. 2016;8(3):25.
23. Shukla SK, Kulkarni NS, Chan A, Parvathaneni V, Farrales P, Muth A, et al. Metformin-encapsulated liposome delivery system: an effective treatment approach against breast cancer. Pharmaceutics. 2019;11(11):559.
24. Du G, Sun X. Ethanol injection method for liposome preparation. Methods Mol Biol. 2023;2622:65–70.
25. Castaneda-Reyes ED, Perea-Flores MJ, Davila-Ortiz G, Lee Y, Gonzalez de Mejia E. Development, characterization and use of liposomes as amphipathic transporters of bioactive compounds for melanoma treatment and reduction of skin inflammation: a review. Int J Nanomedicine. 2020;15:7627–7650.
26. Aleti R, Baratam SR, Jagirapu B, Kudamala S. Formulation and evaluation of metformin hydrochloride and gliclazide sustained-release bilayer tablets: a combination therapy in management of diabetes. Int J Appl Pharm. 2021;13(5):343–350.
27. Lombardo D, Kiselev MA. Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics. 2022;14(3):543.
28. Souto EB, Souto SB, Campos JR, Severino P, Pashirova TN, Zambrano LY, et al. Nanoparticle delivery systems in the treatment of diabetes complications. Molecules. 2019;24(23):4209.
29. Gouda A, Sakr OS, Nasr M, Sammour O. Ethanol injection technique for liposomes formulation: an insight into development, influencing factors, challenges and applications. J Drug Deliv Sci Technol. 2021;61:102174.
30. Ramli NA, Ali N, Hamzah S, Yatim NI. Physicochemical characteristics of liposome encapsulation of stingless bees’ propolis. Heliyon. 2021;7(4):e06649.
31. Hussain M, Hafeez A, Kushwaha SP. Nanoformulation mediated transdermal delivery of anti-diabetic drugs: an updated review. Intell Pharm. 2023;1(4):192–200.
32. Eugster R, Luciani P. Liposomes: bridging the gap from lab to pharmaceuticals. Curr Opin Colloid Interface Sci. 2025;75:101875.
33. Maritim S, Boulas P, Lin Y. Comprehensive analysis of liposome formulation parameters and their influence on encapsulation, stability and drug release in glibenclamide liposomes. Int J Pharm. 2021;592:120051.
34. Jasmin KPM, Battu S, Vishwanath BA. Transferosomes for effective transdermal drug delivery. Int J Pharm Sci Rev Res. 2024;84(4):10–21.
35. Pereira Guimarães DI, da Costa Nogueira ES, Cavaco-Paulo A. Method for production of liposomes. WO2020225769A1. 2020.
36. Almuqbil RM, Aldhubiab B. Ethosome-based transdermal drug delivery: its structural components, preparation techniques, and therapeutic applications across metabolic, chronic, and oncological conditions. Pharmaceutics. 2025;17(5):583.
37. Karande P. The synergistic effect of iontophoresis or electroporation and microneedles on the skin permeation of high molecular weight compounds. Plast Surg Key. 2017 Oct 13.
38. Ozgen G, Ozturk NZA, Turan G, Turk M, Gokce EH, Ozer O, et al. Validation of a simple HPLC/UV method for assay and in vitro release of glycosaminoglycan from pharmaceutical formulations. ACS Omega. 2024;9(50):49023–49031.
39. Raju MG, Srinija KV, Suvarchala Reddy NVL, Keerthana K, Sravya P. Transferosome: a novel transdermal drug delivery system for the treatment of hyperlipidemia. Asian J Med Principles Clin Pract. 2023;6(2):318–326.
40. Donnelly RF, Garland MJ, Alkilani AZ. Microneedle-iontophoresis combinations for enhanced transdermal drug delivery. Methods Mol Biol. 2014;1141:121–132.
41. Nabila FH, Islam R, Li Y, Kawaguchi Y, Wakabayashi R, Kamiya N, et al. Transdermal insulin delivery using ionic liquid-mediated nanovesicles for diabetes treatment. ACS Biomater Sci Eng. 2024;11(1):402–414.
42. Ali SAE, Hussein NGA, El-Kholey SM, Ibrahim EAE, et al. Microneedle combined with iontophoresis and electroporation for assisted transdermal delivery of Goniothalamus macrophyllus for enhanced sono-photodynamic cancer therapy. Sci Rep. 2024;14:7962.
43. Panwar P, Pandey B, Lakhera PC, Singh KP. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomedicine. 2010;5:101–108.
44. Wu XM, Todo H, Sugibayashi K. Enhancement of skin permeation of high molecular compounds by a combination of microneedle pretreatment and iontophoresis. J Control Release. 2007;118(2):189–195.
45. Cipolla D, Wu H, Eastman S, Redelmeier T, Gonda I, Chan HK. Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation. J Pharm Sci. 2014;103(1):314–327.
46. Prashanthini VP, Sivaraman S, Kathirvelu P, Shanmugasundaram J, Subramanian V, Ramesh SS, Karthikeyan E, Cheriyan BV. Transferosomal gel for transdermal delivery of insulin: formulation development and ex vivo permeation study. Intell Pharm. 2023;1(4):212–216.
47. Dhas N, Preetha HS, Dubey A, Ravi G, Govindan I, Rama A, et al. Factorial design-based fabrication of biopolymer-functionalized Asiatic acid-embedded liposomes: in-vitro characterization and evaluation. J Appl Pharm Sci. 2022;12(11):71–81.
48. Singh JP, Saini G, Singh B, Tiwari G. Nano-formulation approaches to enhance transdermal drug delivery: an updated review of nanovesicular carrier “transethosomes”. Pharm Nanotechnol. 2024;13(4):739–757.
49. Li Y, Yang J, Zheng Y, Ye R, Liu B, Huang Y, et al. Iontophoresis-driven porous microneedle array patch for active transdermal drug delivery. Acta Biomater. 2021;121:349–358.
50. Agilent Technologies. Dissolution of a propofol liposomal formulation using the NanoDis method. 2020.
51. Khamkat P, Ghosh A, Mukherjee S. Transfersomes: an innovative vesicular carrier for boosted transdermal delivery system. Res J Pharm Technol. 2022;15(6):2793